Special items: Ovarian Cancer and Us blog best viewed in Firefox

Thursday, March 04, 2010

U.S. - FDA approves a risk evaluation and mitigation strategy (REMS) to ensure the safe use of Erythropoiesis-Stimulating Agents (ESAs)"


No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.